Abstract:The programmed cell death pathway, necroptosis, relies on the pseudokinase, Mixed Lineage Kinase domain-Like (MLKL), for cellular execution downstream of death receptor or Toll-like receptor ligation. Receptor-interacting protein kinase-3 (RIPK3)-mediated phosphorylation of MLKL's pseudokinase domain leads to MLKL switching from an inert to activated state, where exposure of the N-terminal four-helix bundle (4HB) 'executioner' domain leads to cell death. The precise molecular details of MLKL activation, including the stoichiometry of oligomer assemblies, mechanisms of membrane translocation and permeabilisation, remain a matter of debate. Here, we dissect the function of the two 'brace' helices that connect the 4HB to the pseudokinase domain of MLKL. In addition to establishing that the integrity of the second brace helix is crucial for the assembly of mouse MLKL homotrimers and cell death, we implicate the brace helices as a device to communicate pseudokinase domain phosphorylation event(s) to the N-terminal executioner 4HB domain. Using mouse:human MLKL chimeras, we defined the first brace helix and adjacent loop as key elements of the molecular switch mechanism that relay pseudokinase domain phosphorylation to the activation of the 4HB domain killing activity. In addition, our chimera data revealed the importance of the pseudokinase domain in conferring host specificity on MLKL killing function, where fusion of the mouse pseudokinase domain converted the human 4HB + brace from inactive to a constitutive killer of mouse fibroblasts. These findings illustrate that the brace helices play an active role in MLKL regulation, rather than simply acting as a tether between the 4HB and pseudokinase domains.

Discovery and Structure-Based Optimization of Fragments Binding the Mixed Lineage Kinase Domain-like Protein Executioner Domain

Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis

Design, synthesis and anti-necroptosis activity of fused heterocyclic MLKL inhibitors

Discovery of Covalent MLKL PROTAC Degraders via Optimization of a Theophylline Derivative Ligand for Treating Necroptosis

Discovery of a new class of highly potent necroptosis inhibitors targeting the mixed lineage kinase domain-like protein.

Uncovering human mixed lineage kinase domain-like activation in necroptosis

Phosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization

Direct Activation of Human MLKL by a Select Repertoire of Inositol Phosphate Metabolites

From Hit to Lead: Structure-Based Optimization of Novel Selective Inhibitors of Receptor-Interacting Protein Kinase 1 (RIPK1) for the Treatment of Inflammatory Diseases

Death at a funeral: Activation of the dead enzyme, MLKL, to kill cells by necroptosis

Discovery and optimization of 3-(indolin-5-yloxy)pyridin-2-amine derivatives as potent necroptosis inhibitors

N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[ d]thiazol-2-yl)cyclopropanecarboxamide (TAK-632) Analogues as Novel Necroptosis Inhibitors by Targeting Receptor-Interacting Protein Kinase 3 (RIPK3): Synthesis, Structure-Activity Relationships, and in Vivo Efficacy

Modeling the molecular fingerprint of protein-lipid interactions of MLKL on complex bilayers

The brace helices of MLKL mediate interdomain communication and oligomerisation to regulate cell death by necroptosis

The Many Faces of MLKL, the Executor of Necroptosis

Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity

Molecular Insights into the Mechanism of Necroptosis: The Necrosome as a Potential Therapeutic Target

Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis

Harnessing dual-mode RIPK1 ligands for cross-species anti-necroptosis inhibitor compounds

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1

Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis